arrow
C

Claudio Bonifati

department of clinical dermatology, san gallicano dermatological institute, irccs , rome ,
H指数:26
被引数:1,868

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world analysis of IL-23 inhibitors in patients with moderate-to-severe psoriasis and early musculoskeletal symptoms

中重度银屑病患者早期肌肉骨骼症状中IL-23抑制剂的真实世界分析

2025-09-080
OA
A long-term real-world safety study of guselkumab in patients with psoriasis who have infectious comorbidities, malignancies or heart disease: the EARLY study

古塞库单抗在患有感染性合并症、恶性肿瘤或心脏病的银屑病患者中的长期真实世界安全性研究:EARLY研究

2025-04-160
PRE
Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study
2025-04-010
OAAI
Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER study
2024-06-260
PRE
Effectiveness of risankizumab for the treatment of psoriatic arthritis: a multicenter, real-world study

risankizumab治疗银屑病关节炎的有效性: 一项多中心,真实世界研究

2024-04-072
PRE
2-Year Experience with Risankizumab in the Treatment of Plaque Psoriasis in Lazio Region, Italy
2023-09-191
OA
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year

接受guselkumab治疗长达1年的中至重度斑块状银屑病患者的真实结果

2022-06-226
OA
Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study

Risankizumab治疗中重度银屑病: 一项多中心、回顾性、1年真实生活研究

2022-04-1319
OAAI
Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy
2021-07-186
PREAI
Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study
2021-01-0123
OAAI
PsA-Disk, a novel visual instrument to evaluate psoriatic arthritis in psoriatic patients: an Italian derma-rheuma multicentre study
2019-05-145
OAAI